Augmenting drug–carrier compatibility improves tumour nanotherapy efficacy
- Icahn School of Medicine at Mount Sinai, New York, NY (United States); Academic Medical Center, AZ, Amsterdam, (The Netherlands). Department of Medical Biochemistry
- IcaIcahn School of Medicine at Mount Sinai, New York, NY (United States)
- The Norwegian Univ. of Science and Technology, Trondheim, (Norway)
- Weill Cornell Medical College of Cornell Univ., New York, NY (United States); IBM Thomas J. Watson Research Center, Yorktown Heights, NY (United States)
- Icahn School of Medicine at Mount Sinai, New York, NY (United States)
- Icahn School of Medicine at Mount Sinai, New York, NY (United States); Academic Medical Center, Amsterdam (The Netherlands)
- Weill Cornell Medical College of Cornell Univ., New York, NY (United States)
A major goal of cancer nanotherapy is to use nanoparticles as carriers for targeted delivery of anti-tumour agents. The drug–carrier association after intravenous administration is essential for efficient drug delivery to the tumour. However, a large number of currently available nanocarriers are self-assembled nanoparticles whose drug-loading stability is critically affected by the in vivo environment. Here we used in vivo FRET imaging to systematically investigate how drug–carrier compatibility affects drug release in a tumour mouse model. We found the drug’s hydrophobicity and miscibility with the nanoparticles are two independent key parameters that determine its accumulation in the tumour. Next, we applied these findings to improve chemotherapeutic delivery by augmenting the parent drug’s compatibility; as a result, we achieved better antitumour efficacy. Lastly, our results help elucidate nanomedicines’ in vivo fate and provide guidelines for efficient drug delivery.
- Research Organization:
- Oak Ridge National Laboratory (ORNL), Oak Ridge, TN (United States). Oak Ridge Leadership Computing Facility (OLCF); UT-Battelle, LLC, Oak Ridge, TN (United States)
- Sponsoring Organization:
- DOE Office of Science; USDOE
- Grant/Contract Number:
- AC05-00OR22725
- OSTI ID:
- 1258344
- Journal Information:
- Nature Communications, Journal Name: Nature Communications Vol. 7; ISSN 2041-1723
- Publisher:
- Nature Publishing GroupCopyright Statement
- Country of Publication:
- United States
- Language:
- English
Similar Records
Tumor Retention of Enzyme-Responsive Pt(II) Drug-Loaded Nanoparticles Imaged by Nanoscale Secondary Ion Mass Spectrometry and Fluorescence Microscopy
Nanostructured nanoparticles of self-assembled lipid pro-drugs as a route to improved chemotherapeutic agents
Intrinsic and Stable Conjugation of Thiolated Mesoporous Silica Nanoparticles with Radioarsenic
Journal Article
·
Mon Oct 22 20:00:00 EDT 2018
· ACS Central Science
·
OSTI ID:1508250
Nanostructured nanoparticles of self-assembled lipid pro-drugs as a route to improved chemotherapeutic agents
Journal Article
·
Wed Sep 24 00:00:00 EDT 2014
· Nanoscale
·
OSTI ID:1021192
Intrinsic and Stable Conjugation of Thiolated Mesoporous Silica Nanoparticles with Radioarsenic
Journal Article
·
Sun Feb 05 19:00:00 EST 2017
· ACS Applied Materials and Interfaces
·
OSTI ID:1463090